MEET THE NORTHSKY TEAM

Rob Harris, past founder and President and CEO of Tribute Pharmaceuticals, has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management.  

Rob most recently served as Executive Chair of Nuvo Pharmaceuticals Inc.  Rob also has previous experience at Biovail Corporation as VP of Business Development where he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Rob joined Biovail in 1997 as the General Manager of Biovail 

Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division. Before Biovail, Rob worked in various senior commercial management positions during his twenty-year tenure at Wyeth-Ayerst (now Pfizer Inc.), including its animal health group and has been involved in numerous product launches during his career.  

Rob also serves as a member of the Board of Directors of Trudell Medical Group and Grey Wolf Animal Health. Previous board experience includes Nuvo Pharmaceuticals Inc., Origin House, Tribute Pharmaceuticals, Aralez Pharmaceuticals Inc. and  Stellar Pharmaceuticals Inc. 

Jesse brings more than 20 years of experience building pharmaceutical businesses 

and securing growth capital, with extensive Canadian, U.S., and international 

operational and transactional expertise, including nearly $1 billion in completed 

M&A transactions.

Prior to co-founding NorthSky Pharma, Jesse was President & CEO of Miravo 

Healthcare, a publicly listed Canadian specialty pharmaceutical company that 

was acquired by Searchlight Pharma Inc. in March 2023. From 2017 to 2023, 

he led Miravo’s transformation from a break-even, manufacturing-focused 

organization into a fully integrated, highly profitable global pharmaceutical 

business specializing in allergy, dermatology, and pain management therapeutics.

Jesse later served as Chief Strategy & Corporate Development Officer at Searchlight 

Pharma Inc. until the company’s acquisition by Apotex Inc. in June 2025. In that role, 

he led global business and corporate development initiatives and oversaw 

Searchlight’s international operations based in Dublin, Ireland.

Before Miravo, Jesse served as Vice President, Business Development & International 

Business at Tribute Pharmaceuticals Canada Inc., where he was part of the senior 

management team, led by Rob Harris, that built a profitable specialty pharmaceutical 

business across Canada, Europe, and the United States. This period culminated in 

Tribute’s merger with Pozen Inc. and the subsequent formation of Aralez 

Pharmaceuticals Inc. Group and Grey Wolf Animal Health. 

Previous board experience includes Nuvo Pharmaceuticals Inc., Origin House, 

Tribute Pharmaceuticals, Aralez Pharmaceuticals Inc. and Stellar Pharmaceuticals Inc.

Ms. Demerino is a seasoned pharmaceutical industry executive with over 20 years of experience in diverse industries, including healthcare, clean energy, manufacturing, and financial institutions.  

Kelly has held numerous senior leadership roles, ranging from CFO at Cyclone Manufacturing Inc, an aerospace manufacturer; Interim CFO for Nuvo Pharmaceuticals Inc. and VP Finance for Miravo Healthcare. Her diverse experience includes raising capital via public offerings and private placements, M&A integrations, product launches, and the execution of in-licensing and out-licensing deals.

Kelly is a Chartered Professional Accountant (CPA), a Chartered Accountant (CA), and a Certified Internal Auditor (CIA), and holds a Bachelor of Commerce degree from Mount Allison University.

Dr. Chiasson has approximately 30 years’ experience in research and development and executive management roles in pharmaceuticals and biotechnology. 

In his most recent role as VP Operations and Chief Scientific Officer at Nuvo Pharmaceuticals Inc., he was responsible for oversight of regulatory, safety, medical/clinical and quality. As part of his operational duties, Bernard also oversaw supply chain and in-house and outsourced manufacturing and was a member of the Board of Directors at Nuvo Pharmaceuticals DAC in Ireland. Bernard is currently President of BJC Integrated Scientific Management Inc., a boutique consulting firm that provides management consulting in various scientific areas. 

He has worked on small molecules, biologics and medical devices at various stages of product development including the final registration phase with Health Canada and the US FDA. He is experienced in a variety of therapeutic areas and has developed strategies and franchise management approaches for pre-market and marketed products in various categories. 

Bernard obtained his industry training with Novartis, Draxis Health, Bayer Biologics, Amgen, Tribute Pharmaceuticals, Nuvo Pharmaceuticals and held the position of Vice President of Strategic Regulatory Affairs and Medical Services at Optum. 

Dr. Chiasson is a trained neuroscientist and pharmacologist and received his training at Dalhousie University and the University of Toronto.